Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PSNL logo PSNL
Upturn stock ratingUpturn stock rating
PSNL logo

Personalis Inc (PSNL)

Upturn stock ratingUpturn stock rating
$5.35
Delayed price
Profit since last BUY-12.15%
upturn advisory
Regular Buy
BUY since 12 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/13/2025: PSNL (3-star) is a REGULAR-BUY. BUY since 12 days. Profits (-12.15%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -25.72%
Avg. Invested days 22
Today’s Advisory Regular Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/13/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 453.11M USD
Price to earnings Ratio -
1Y Target Price 7.98
Price to earnings Ratio -
1Y Target Price 7.98
Volume (30-day avg) 1197616
Beta 1.95
52 Weeks Range 1.12 - 7.20
Updated Date 01/13/2025
52 Weeks Range 1.12 - 7.20
Updated Date 01/13/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.66

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -104.52%
Operating Margin (TTM) -55.94%

Management Effectiveness

Return on Assets (TTM) -18.78%
Return on Equity (TTM) -57.52%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 354612694
Price to Sales(TTM) 5.18
Enterprise Value 354612694
Price to Sales(TTM) 5.18
Enterprise Value to Revenue 4.29
Enterprise Value to EBITDA -0.03
Shares Outstanding 84693000
Shares Floating 38224852
Shares Outstanding 84693000
Shares Floating 38224852
Percent Insiders 32.66
Percent Institutions 44.4

AI Summary

Personalis Inc. (PSNL): A Comprehensive Overview

Company Profile:

Detailed history and background: Personalis Inc. was founded in 2011 as Personalis, Inc., a Delaware corporation, and later reincorporated as Personalis, Inc. a Delaware corporation, in 2020. The company is a next-generation cancer diagnostics and immune-oncology therapy company focused primarily on developing and commercializing technologies to unlock the power of the immune system to treat and prevent cancer.

Core business areas: Personalis operates in two key areas:

  • Clinical diagnostics: This segment develops and commercializes tests that assess a patient's tumor's genomic and immune landscape to enable personalized medicine approaches to cancer care. Their NeXT Platform® is a proprietary next-generation sequencing (NGS) technology platform that analyzes the entire exome of a patient's tumor and normal tissue, providing detailed information about the tumor's mutations, gene expression, and immune infiltrates. This information helps oncologists make informed treatment decisions, including targeted therapies and immune checkpoint inhibitors.
  • Immune-oncology therapies: This segment focuses on developing novel cancer vaccine therapies based on the insights gained from the NeXT Platform. Personalis is currently developing a neoantigen-based vaccine, P1-001, which is in Phase 1/2 clinical trials. This vaccine is designed to activate the patient's own immune system to recognize and attack the tumor.

Leadership team and corporate structure: Personalis is led by an experienced team of executives with expertise in cancer biology, diagnostics, and drug development. Dr. John West is the President and CEO, Dr. Joshua LaBaer is the Chief Scientific Officer, and Mr. David Stickle is the Chief Financial Officer. The company has a Board of Directors composed of industry veterans with diverse backgrounds in finance, healthcare, and technology.

Top Products and Market Share:

Top Products:

  • NeXT Platform: This is the company's flagship product, offering comprehensive genomic and immune profiling of tumors for personalized cancer care.
  • P1-001: This is a neoantigen-based cancer vaccine currently in Phase 1/2 clinical trials.

Market Share:

  • NeXT Platform: Personalis estimates its market share for clinical diagnostic NGS in the US at approximately 10%.
  • P1-001: As a novel therapy, P1-001 does not yet have a market share.

Comparison with Competitors:

  • NeXT Platform: Personalis faces competition from other NGS-based diagnostic players like Foundation Medicine (FMI), Illumina (ILMN), and Guardant Health (GH). Compared to competitors, NeXT Platform offers a more comprehensive analysis of the tumor's genomic and immune landscape.
  • P1-001: This therapy competes with other personalized cancer vaccines in development. Personalis believes its technology and personalized approach may provide a competitive edge.

Total Addressable Market:

The global cancer diagnostics market is estimated to be over $20 billion and is expected to grow at a CAGR of over 10% in the next few years. Personalis estimates the US addressable market for its diagnostic business at approximately $5 billion. The market for personalized cancer vaccines is expected to grow significantly in the coming years, but the exact size is still developing.

Financial Performance:

Revenue and Net Income: Personalis' revenue has grown steadily over the past few years, reaching $88.1 million in 2022. However, the company is not yet profitable, reporting a net loss of $119.1 million in 2022.

Profit Margins and EPS: Personalis's gross margin is currently around 40%, while its operating margin is negative. The company's EPS is also negative.

Cash Flow and Balance Sheet: Personalis has a strong cash position, with over $280 million in cash and equivalents as of December 31, 2022. However, the company has negative operating cash flow due to its ongoing research and development investments.

Dividends and Shareholder Returns:

Dividend History: Personalis does not currently pay dividends, as it is focused on reinvesting its resources into growth.

Shareholder Returns: Over the past year, Personalis stock has experienced significant volatility. However, over the past five years, the stock has generated positive returns for shareholders.

Growth Trajectory:

Historical Growth: Personalis has experienced strong revenue growth over the past few years. However, the company is still in the early stages of commercializing its products and is not yet profitable.

Future Projections: Industry analysts expect Personalis to continue to grow its revenue in the coming years as it expands its commercial reach and launches new products. However, the company's profitability remains uncertain.

Recent Initiatives: Personalis is actively pursuing several initiatives to drive future growth, including expanding its commercial team, developing new partnerships, and launching new products.

Market Dynamics:

Industry Trends: The cancer diagnostics and immunotherapy markets are experiencing rapid growth, driven by technological advancements and a growing understanding of the immune system's role in cancer.

Personalis' Positioning: Personalis is positioned to benefit from these trends with its innovative technologies and focus on personalized medicine.

Competitors:

Key Competitors: Personalis's key competitors include Foundation Medicine (FMI), Natera (NTRA), Guardant Health (GH), Illumina (ILMN), and Adaptive Biotechnologies (ADPT).

Market Share Comparison: Personalis has a smaller market share than some of its larger competitors, but its NeXT Platform offers a more comprehensive analysis of the tumor's genomic and immune landscape.

Competitive Advantages and Disadvantages: Personalis's advantages include its innovative NeXT Platform, its proprietary technology, and its focus on personalized medicine. However, the company faces challenges due to its small size, lack of profitability, and intense competition.

Potential Challenges and Opportunities:

Key Challenges: Personalis faces several challenges, including:

  • Competition: The company operates in a highly competitive market with several established players.
  • Lack of profitability: Personalis is not yet profitable and may require additional funding to continue its operations.
  • Regulatory hurdles: The development and commercialization of new diagnostic tests and therapies

About NVIDIA Corporation

Exchange NASDAQ
Headquaters Fremont, CA, United States
IPO Launch date 2019-06-20
President, CEO & Director Mr. Christopher M. Hall
Sector Healthcare
Industry Diagnostics & Research
Full time employees 223
Full time employees 223

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​